Deal Watch: Boehringer’s Busy Week – An Acquisition, A Divestiture And A Discontinuation

Teva’s buyout of Allergan’s generics business should end speculation about a Teva/Mylan merger. A new Sanofi/Regeneron tie-up and an AstraZeneca divestiture to Sanofi’s Genzyme unit are among the latest developments in immuno-oncology.

More from Archive

More from Pink Sheet